Makiko Ono1, Hitoshi Tsuda2, Masayuki Yoshida3, Chikako Shimizu4, Takayuki Kinoshita5, Kenji Tamura4. 1. Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. 2. Department of Basic Pathology, National Defense Medical College, Saitama, Japan; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan. Electronic address: htsuda@ndmc.ac.jp. 3. Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan. 4. Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. 5. Department of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan.
Abstract
INTRODUCTION: We showed the clinical implications of the Ki-67 labeling index (LI) in hormone receptor (HR)-positive, HER2-negative (HER2-) breast cancer patients with lower risk (luminal A [LA]-like) and higher risk (luminal B [LB]-like) subtypes. PATIENTS AND METHODS: Three hundred sixty-nine patients with HR+, HER2- cancers were eligible and we dichotomized these patients into LA-like and LB-like according to Ki-67 LI (14% cutoff) and analyzed prognostic significance of progesterone receptor (PR) expression. RESULTS: Of 205 LA-like and 163 LB-like subtypes, PR was positive in 149 (73%) and 103 (63%). PR expression was a prognostic factor in the LA-like subtype but not in the LB-like subtype. In LA/PR+, LA/PR-, and LB-like subtypes, the 12-year disease-free survival (DFS) rates were 94.8%, 81.6%, and 79.7% (P = .03), and breast cancer-specific survival (BCSS) rates were 98.4%, 97.4%, and 92.0%, respectively (P = .05). Late recurrence occurred in LA/PR- subtype, and differences in prognosis between LA/PR+ and LA/PR- subtypes emerged >5 years after surgery. Twelve-year DFS rates of the LA/PR- subtype were almost equal to those of the LB-like subtype, whereas 12-year BCSS of the LA/PR- subtype was superior to that of the LB-like subtype. In multivariate analysis, PR expression and tumor size were significant or nearly significant prognostic factors. CONCLUSION: PR expression and tumor size were independent prognostic factors in the LA-like subtype, and the LA/PR- subtype had the higher risk of recurrence, especially late recurrence, than the LA/PR+ subtype. In LA-like breast cancers, stratification of prognosis according to PR expression and tumor size is important.
INTRODUCTION: We showed the clinical implications of the Ki-67 labeling index (LI) in hormone receptor (HR)-positive, HER2-negative (HER2-) breast cancerpatients with lower risk (luminal A [LA]-like) and higher risk (luminal B [LB]-like) subtypes. PATIENTS AND METHODS: Three hundred sixty-nine patients with HR+, HER2- cancers were eligible and we dichotomized these patients into LA-like and LB-like according to Ki-67 LI (14% cutoff) and analyzed prognostic significance of progesterone receptor (PR) expression. RESULTS: Of 205 LA-like and 163 LB-like subtypes, PR was positive in 149 (73%) and 103 (63%). PR expression was a prognostic factor in the LA-like subtype but not in the LB-like subtype. In LA/PR+, LA/PR-, and LB-like subtypes, the 12-year disease-free survival (DFS) rates were 94.8%, 81.6%, and 79.7% (P = .03), and breast cancer-specific survival (BCSS) rates were 98.4%, 97.4%, and 92.0%, respectively (P = .05). Late recurrence occurred in LA/PR- subtype, and differences in prognosis between LA/PR+ and LA/PR- subtypes emerged >5 years after surgery. Twelve-year DFS rates of the LA/PR- subtype were almost equal to those of the LB-like subtype, whereas 12-year BCSS of the LA/PR- subtype was superior to that of the LB-like subtype. In multivariate analysis, PR expression and tumor size were significant or nearly significant prognostic factors. CONCLUSION:PR expression and tumor size were independent prognostic factors in the LA-like subtype, and the LA/PR- subtype had the higher risk of recurrence, especially late recurrence, than the LA/PR+ subtype. In LA-like breast cancers, stratification of prognosis according to PR expression and tumor size is important.
Authors: Soo Yeon Baek; Ji Yeong Kwon; Young Joo Lee; Sung-Chan Gwark; Sae Byul Lee; Jisun Kim; Il Yong Chung; Beom Seok Ko; Hee Jeong Kim; Sung-Bae Kim; Seung Do Ahn; Gyungyub Gong; Byung Ho Son; Sei-Hyun Ahn; Jong Won Lee Journal: J Breast Cancer Date: 2019-08-01 Impact factor: 3.588
Authors: Richard Sleightholm; Beth K Neilsen; Safwan Elkhatib; Laura Flores; Saihari Dukkipati; Runze Zhao; Songita Choudhury; Bret Gardner; Joey Carmichael; Lynette Smith; Nathan Bennion; Andrew Wahl; Michael Baine Journal: J Clin Med Res Date: 2021-01-12